Wall Street analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings per share (EPS) of ($0.78) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.89) and the highest estimate coming in at ($0.57). The business is expected to issue its next earnings results on Thursday, March 14th.

On average, analysts expect that Crispr Therapeutics will report full year earnings of ($3.26) per share for the current fiscal year, with EPS estimates ranging from ($3.33) to ($3.08). For the next financial year, analysts anticipate that the business will post earnings of ($3.47) per share, with EPS estimates ranging from ($4.05) to ($1.86). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.33). The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $2.64 million. Crispr Therapeutics had a negative return on equity of 40.41% and a negative net margin of 331.84%. The business’s revenue was down 76.6% on a year-over-year basis. During the same period last year, the company earned ($0.62) EPS.

A number of equities analysts have recently weighed in on CRSP shares. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Needham & Company LLC started coverage on Crispr Therapeutics in a research note on Friday, November 30th. They issued a “buy” rating and a $62.00 price objective for the company. Zacks Investment Research lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 3rd. Finally, Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Monday, September 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and an average price target of $62.42.

Shares of NASDAQ CRSP traded down $0.42 during mid-day trading on Friday, reaching $35.92. The company’s stock had a trading volume of 616,500 shares, compared to its average volume of 1,172,666. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -20.80 and a beta of 3.79. Crispr Therapeutics has a 52 week low of $17.40 and a 52 week high of $73.90.

Large investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $116,000. TRUE Private Wealth Advisors purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $122,000. Signaturefd LLC lifted its position in shares of Crispr Therapeutics by 123.8% in the second quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares in the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of Crispr Therapeutics by 202.9% in the second quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after buying an additional 1,826 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Crispr Therapeutics by 66.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after buying an additional 1,127 shares in the last quarter. Institutional investors own 43.88% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Article: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.